Stage 4 cervical cancer means the cancer has grown beyond the cervix and surrounding tissues and has either invaded nearby organs like the bladder or rectum, or spread to distant parts of the body such as the lungs, liver, or bones. It is the most advanced stage of cervical cancer and is divided into two substages, 4A and 4B, which differ significantly in how the disease behaves and how it’s treated.
Stage 4A vs. Stage 4B
The distinction between these two substages matters because it shapes the entire treatment approach. Stage 4A means the tumor has grown directly into the lining of the bladder or rectum, or has extended beyond the boundaries of the pelvis. The cancer is still regional, not in distant organs, but it has invaded structures immediately surrounding the cervix.
Stage 4B means the cancer has metastasized to distant organs or lymph nodes far from the pelvis. The lungs are the most common site, accounting for about 37% of single-organ metastases. The liver is next at roughly 17.5%, followed by bone at 15%. Brain metastasis is less common, occurring in about 3.4% of cases. Some patients have cancer in more than one distant organ at diagnosis, with the lung-and-liver combination being the most frequent pattern.
How Stage 4 Is Diagnosed
Doctors use a combination of imaging and physical examination to determine whether cervical cancer has reached stage 4. MRI is particularly reliable for ruling out bladder or rectal invasion. When MRI shows no signs of tumor in those organs, it’s accurate enough to avoid more invasive procedures like cystoscopy (a camera exam of the bladder).
For detecting distant spread, PET/CT scanning is the most informative tool. It combines metabolic imaging, which highlights areas of high cancer activity, with detailed anatomic CT images. This is more accurate than CT alone, especially for spotting cancer in lymph nodes, bones, the liver, and other sites outside the pelvis. In some cases, PET/CT reveals unexpected metastases, such as cancer in lymph nodes above the collarbone, that change the treatment plan entirely. About 8% of patients with advanced disease are found to have these distant lymph node sites that would otherwise be missed.
Symptoms at This Stage
The symptoms of stage 4 cervical cancer depend heavily on where the cancer has spread. Many people experience persistent fatigue, abdominal pain or bloating, constipation, and sometimes vomiting. Vaginal bleeding, which may have been an early symptom, often continues or worsens.
When the cancer invades the bladder or rectum (stage 4A), it can cause blood in the urine or stool, changes in bladder or bowel habits, and in some cases an abnormal connection called a fistula between the vagina and bladder or rectum. This can lead to leakage of urine or stool through the vagina.
Bone metastasis causes a distinctive type of pain: a deep, persistent ache that tends to wake you at night and doesn’t improve with rest. Affected bones are also more vulnerable to fractures. Cancer cells can block lymph fluid from draining properly, leading to swelling in the legs or abdomen, a condition known as lymphedema. When the tumor grows large enough to press on the tubes that drain urine from the kidneys (the ureters), it can cause kidney blockage, which may require a drainage procedure to protect kidney function.
Treatment for Stage 4A
When the cancer has invaded the bladder or rectum but hasn’t spread to distant organs, the primary treatment is radiation therapy combined with chemotherapy. Platinum-based chemotherapy drugs are given alongside radiation because they make the radiation more effective. This combined approach, called chemoradiation, is the standard first-line treatment and aims to shrink the tumor and control local disease.
For some patients with 4A disease, the tumor responds well enough that it’s controlled for an extended period. Others may need additional treatments if the cancer persists or returns.
Treatment for Stage 4B
Once cervical cancer has spread to distant organs, the goals of treatment shift. Cure becomes much less likely, and treatment focuses on slowing the cancer’s growth, relieving symptoms, and extending life as much as possible.
Chemotherapy is the backbone of treatment at this stage. Adding a drug that blocks the growth of blood vessels feeding the tumor has been shown to extend survival. A major clinical trial found that this combination improved median overall survival from 13.3 months to 16.8 months compared to chemotherapy alone.
Immunotherapy has also become an option for some patients. The FDA approved the immunotherapy drug pembrolizumab for patients with metastatic or recurrent cervical cancer whose tumors test positive for a protein called PD-L1. This protein signals that the immune system may respond to treatment. Patients whose tumors don’t express this marker showed no response to the drug, so testing is required before it’s used. Immunotherapy can be given alone or alongside chemotherapy and other targeted treatments.
Palliative chemotherapy, sometimes combined with targeted therapy, is used specifically to manage symptoms like pain and bleeding even when it isn’t expected to eliminate the cancer. Radiation can also be directed at specific areas, such as painful bone metastases, to provide relief.
Managing Kidney Blockage
One of the more common complications of advanced cervical cancer is ureteral obstruction, where the growing tumor presses on the tubes connecting the kidneys to the bladder. Left untreated, this can cause kidney damage or failure. About 81% of patients with this complication undergo a drainage procedure.
There are two main approaches: a tube placed through the skin directly into the kidney (called a nephrostomy) or a small tube threaded up through the bladder into the ureter (a ureteral stent). Both carry similar complication rates, with infection, pain, and blood in the urine being the most common issues. However, ureteral stents are nearly three times more likely to fail initially and need replacement compared to the external drainage tube.
Survival and Outlook
The 5-year relative survival rate for cervical cancer that has spread to distant parts of the body is 19%, according to data from the National Cancer Institute. This means that about 1 in 5 people diagnosed with distant-stage cervical cancer are alive five years later, compared to people without the disease.
That number is a population average and doesn’t predict any individual’s outcome. Survival varies based on where and how extensively the cancer has spread, how well it responds to treatment, the patient’s overall health, and whether the tumor has markers that make it eligible for newer therapies like immunotherapy. The introduction of targeted therapy and immunotherapy over the past decade has expanded options for patients who previously had few alternatives beyond standard chemotherapy.
Stage 4A disease, because it’s still contained to the pelvic region, generally carries a better prognosis than 4B, where the cancer has reached distant organs. Patients with a single site of metastasis also tend to do better than those with cancer in multiple organs.